Taken together, we deduced that miR-337-3p can be a therapeutic target of tendinopathy through downregulating chondro-osteogenic differentiation of rTDSCs by targeting IRS1 and Nox4 as elucidated in the schematic diagram (Figure 7). This evidence concerns the gene IRS1 and disease of the tendon.